Chronic hepatitis B

By A. Lok, B. McMahon. Hepatology, 2001

1,623 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/1eefe23a84d7d6e9ca081f89a3c5e0c1158cb07b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. G. Dusheiko
2. X. Forns
3. J. Pawlotsky

In Hepatology

1. D. Moradpour
2. G. Dusheiko
3. X. Forns
4. J. Pawlotsky

Citations in the corpus

• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. (2006, neutral): “Yes 451 ( 12 ) 4928 42 852 2.6 (1.8-3.7) .001”
• EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009, background): “(1) The ''immune tolerant " phase is characterized by HBeAg positivity, high levels of HBV replication (reflected by high levels of serum HBV DNA), normal or low levels of aminotransferases, mild or no liver necroinflammation and no or slow progression of fibrosis [3] [5].”
• 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis (2016, positive): “Recommendations related to immunization and treatment in patients with RA and coexistent viral hepatitis B or C were informed primarily by the CDC (138) and the AASLD guidelines (85,86), respectively, and ACR RA TREATMENT RECOMMENDATIONS 19”